A Study to Evaluate Nivolumab in Patients With Unresectable Advanced/Metastatic Gastric Cancer and Gastroesophageal Junction Cancer

Bristol-Myers Squibb (BMS)

Status: Completed

Conditions: Gastroesophageal Junction Cancer; Gastric Cancer

Treatments: Drug: Nivolumab

Study type: Observational

Funder types: Industry

Identifiers

NCT06452329

CA209-1429

Details and patient eligibility

About

The purpose of this study is to collect and evaluate real-world data to enhance understanding of the effectiveness, and treatment patterns of first-line nivolumab treatment in patients with unresectable advanced or metastatic gastric cancer/gastroesophageal junction cancer (GC/GEJC) in China

Enrollment: 260 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Participants aged ≥ 18 years at date of first administration of nivolumab
• Confirmed diagnosis of unresectable advanced or metastatic Gastric Cancer (GC) or Gastroesophageal Junction Cancer (GEJC) (histologically or cytologically)
• Participants newly received nivolumab as first-line (1L) treatment between 15 June 2018 and 30 June 2023
• Participants with at least one tumor assessment after index date except for death or discontinuation due to Adverse Events

Exclusion criteria

• Participants with primary malignancies other than unresectable advanced or metastatic GC/GEJC
• Participants who participate in an interventional clinical trial in or before 1L nivolumab treatment for advanced/metastatic GC/GEJC
• Participants with known HER2 status positive
• Participants who investigator deems inappropriate for inclusion, for example clinical data was incomplete

Trial design

260 participants in 1 patient group

Participants who received first-line nivolumab therapy for advanced GC/GEJC

Treatment:

Drug: Nivolumab